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Mucoadhesive buccal patch releasing drug in the oral cavity at a predetermined rate may present distinct 
advantages over traditional dosage forms, such as tablets, gels and solutions. A buccal patch for systemic 
administration of acyclovir in the oral cavity was developed using polymers hydroxy propyl methyl 
cellulose (K4M), hydroxy propyl methyl cellulose (K15M), sodium carboxy methyl cellulose and poly 
vinyl pyrolidone (K30), plasticizer poly ethylene glycol (400) and a backing membrane of Eudragit 
(RL100). The films were evaluated in terms of swelling, residence time, mucoadhesion, release, and 
organoleptic properties. The optimized films showed lower release as compared to controlled drug 
delivery systems. Hence, an inclusion complex of acyclovir was prepared with hydrophilic polymer 
hydroxylpropyl beta-cyclodextrin in the molar ratio of 1:1. The inclusion complex was characterized 
by optical microscopy, FAB mass spectroscopy, and FTIR spectroscopy. Patches formulated with the 
acyclovir inclusion complex were evaluated along the same lines as those containing acyclovir alone. 
The in vitro release data revealed a substantial increase from 64.35% to 88.15% in the case of PS I and 
PS II batches, respectively, confirming the successful use of inclusion complexes for the formulation 
of buccal patch of acyclovir.
Uniterms: Buccal patches/drug release. Inclusion complexes/use. Acyclovir. Mucoadhesion. 
Mucoadesivos bucais liberadores de fármacos para a cavidade oral com taxa de liberação pré-
determinada podem apresentar distintas vantagens em relação às formas farmacêuticas convencionais 
como comprimidos, géis e soluções.  Neste trabalho, um adesivo bucal para administração sistêmica 
de aciclovir através da cavidade oral foi desenvolvido empregando-se os polímeros hidroxipropilmetil 
celulose (K4M), hidroxipropilmetil celulose (K15M), carboximetil celulose sódica e polivinil pirrolidona 
(K30), polietilenoglicol plastificado (400) e uma membrana suporte de Eudragit (RL100). Os filmes 
obtidos foram avaliados em termos de intumescimento, tempo de residência, mucoadesão, liberação e 
propriedades organolépticas. Os filmes otimizados apresentaram liberação mais lenta em comparação 
a outros sistemas de liberação controlada. Desta maneira, um complexo de inclusão de aciclovir foi 
preparado com o polímero hidrofílico hidroxipropil beta-ciclodextrina em proporções molares 1:1. 
O complexo de inclusão foi caracterizado por microscopia ótica, espectrometria de massas FAB e 
espectroscopia FTIR. Os adesivos formulados com o complexo de inclusão de aciclovir foram avaliados 
em paralelo com adesivos contendo aciclovir isolado. Os dados de liberação in vitro revelaram um aumento 
substancial, de 64,34% para 88,15%, nos lotes PS I e PS II, respectivamente, confirmando o sucesso do 
uso de complexos de inclusão para a formulação de adesivos bucais de aciclovir.
Uniterms: Adesivos bucais/sistema de liberação. Complexos de inclusão/uso. Acyclovir. Mucoadesão. 
INTRODUCTION
Buccal delivery of drugs provides an attractive 
alternative to the oral route of drug administration, par-
ticularly in overcoming the disadvantage associated with 
the latter. Problems such as first pass metabolism and drug 
degradation in the harsh gastrointestinal environment can 
be circumvented by administering drugs via the buccal 
route. Moreover, the oral cavity is easily accessible for 
self-medication and can be promptly terminated in case 
of toxicity by simply removing the dosage form from the 
buccal cavity. Buccal delivery also enables administerings 
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drugs to patients who cannot be dosed orally via this route 
(Shojaei, 1998). Many mucoadhesive buccal films have 
been formulated to release drugs locally in order to treat 
for fungal infections in the oral cavity, such as oral candi-
diasis (Donnelly et al., 2007; Khanna et al., 1997; Rapka 
et al., 2003; Senel et al., 2000). Due to the versatility of 
the manufacturing processes, the release can be oriented 
either towards the buccal mucosa or towards the oral cav-
ity (Morales, McConville, 2011). These dosage forms are 
usually prepared by casting a solution of the polymer, drug 
and any excipients (such as a plasticizer) on to a surface 
and allowing it to dry. Patches can be made 10–15 cm2 in 
size but are more frequently 1–3 cm2, and may present with 
an ellipsoid shape, so as to fit comfortably onto the centre 
of the buccal mucosa (Patel et al., 2011)
Acyclovir is the most effective antiviral drug against 
herpes simplex infection. The oral absorption of acyclovir 
is dose dependent and highly variable, with bioavailability 
ranging from 15-30%. Percutaneous absorption of acyclo-
vir is poor (Shojaei, 1998). The main drawbacks associated 
with this drug are gastric irritation, first pass metabolism 
and low oral bioavailability. Side effects associated with 
topical application of drug consist of stinging and burning 
sensation. However, on oral application, the drug is well 
tolerated. In case of intravenous administration, rashes, 
sweating and emesis are observed. Therefore, there is a 
need to formulate an oral delivery system for acyclovir 
that promotes systemic delivery, bypass of first pass me-
tabolism and improved bioavailability.
Complexation with cyclodextrins has been reported 
to enhance the solubility, dissolution and bioavailability 
of poorly water-soluble drugs, once they are known to 
encapsulate drugs into their hydrophobic cavity without 
the formation of any bonds (Baboota, Agarwal, 2003; 
Fernandes et al., 2002).
The present study is aimed at formulating patches to 
act as transmucosal drug delivery systems containing the 
drug acyclovir and compare these with patches made with 
an inclusion complex of acyclovir, in order to improve oral 
bioavailability.
MATERIAL AND METHODS
Acyclovir was obtained as gift sample from Cipla 
Ltd. (Mumbai, India). Two different polymer grades of 
hydroxy propyl methyl cellulose, HPMC K4M and 
HPMCK15M, poly methacylic acid-co-methyl methacry-
late(1:1) (Eudragit RL100) were obtained from Colorcon 
Asia Pvt. Ltd. (Goa, India) and Cadila Ltd. (Ahemdabad, 
India). Poly vinyl pyrolidone (PVPK30) and hydroxy-
propyl beta cyclodextrin (HPBCD) were obtained as gift 
samples from S.D.Fine-Chem Ltd. Mumbai, India and 
S.A. Pharma. Chem. Pvt. Limited (Mumbai, India). SCMC 
(sodium carboxymethyl cellulose) was obtained from 
Central Drug House (New Delhi, India).
Preparation of patches
The buccal patches were prepared using the solvent 
casting method. Three different polymers were used 
(HPMC K4M, HPMC K15M and SCMC), along with 
plastisizer (PEG 400) and a hydrophilic polymer (PVP 
K30), so that the patch could be made pliable. The quan-
tity of different polymers was optimized as per details in 
Table I. The quantity of acyclovir was kept constant at 10 
mg. Weighed quantities of polymer, plasticizer and hydro-
philic polymer were obtained. The drug and polymer were 
gradually added to 10 ml of distilled water (at 90 °C), with 
constant stirring. The plasticizer and hydrophilic polymer 
were each added as per formula (Table I) after cooling 
the polymer solution to room temperature. This solution 
was then poured in glass Petri dishes (3.9 cm radius and 
1 cm height). The Petri dishes were stored in an incuba-
tor at 37 °C and patches were obtained by evaporation of 
solvent. The patches were then properly removed and cut 
in 10 mm diameter patches (Kashappa, Desai, 2004). A 
backing membrane, containing 2% w/v of Eudragit RL 
100 in acetone and plasticizer, was prepared according to 
the procedure described above and attached to each patch 
using adhesive (Table I).
Evaluation of patches with acyclovir
Thickness uniformity of the patches
Three patches of each formulation were set aside 
for measuring patch thickness using a micrometer screw 
gauge at three different places. The mean value was then 
recorded (Kashappa, Desai, 2004).
Weight uniformity of the patches
For evaluation of patch weight, three patches of 
each formulation were individually weighed on a digital 
balance (ATX 224, Shimadzu, Japan). Mean weight was 
then calculated for each formulation (Nafee, 2003).
Surface pH of patches
To determine surface pH, three patches of each 
formulation were allowed to swell for two hours on the 
surface of an agar plate. Surface pH was measured by us-
ing pH paper placed on the surface of the swollen patch as 
per reported method (Patel and Poddar, 2009) (Table III). 
A mean of three readings was recorded. 
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Swelling index
The swelling index was measured using the diameter 
method. The agar solution was prepared by dissolving 
0.2 g of agar in 10 mL of warmed simulated saliva fluid, 
pH 6.8 (50-70 ºC). This solution was then poured into 
a Petri dish and allowed to cool. After determining the 
initial patch diameter, each patch was allowed to swell on 
its respective surface of gel. The diameters of the patch 
were determined after 2, 5 and 7 hours, and results were 
recorded as the mean value of three readings. Swelling 
studies were performed for 7 hours because a residence 
time of 7 hours was recommended (Baboota, Dhaliwal, 
2005) (Table IV).
The observations were recorded for three optimized 
formulations: PS1, PE1, PH2.
Swelling index = {(Df-Di) / Di}x 100,
where Di = initial patch diameter and Df = final patch 
diameter.
Folding endurance
Three patches of each formulation of bigger size, 
i.e., 2 x 2 cm, were cut using a sharp blade. Folding endur-
ance was determined by repeatedly folding a small strip 
of patch at the same place until it ruptured. The number of 
times the patch could be folded at the same place without 
breaking resulted in the folding endurance value. The 
mean value was calculated and recorded (Alix, Ghania, 
2003) (Table III).
Ex-vivo mucoadhesive strength
Mucoadhesive strength of the patch was measured 
using a modified two arm balance (Mario, Becirerics, 
2004; Kashappa, Desai, 2004). Rabbit buccal mucosa used 
in the procedure was obtained from a local slaughterhouse 
and stored in simulated saliva fluid with a pH of 6.8 at 
4 ºC. The experiment was performed within three hours 
of procurement of the mucosa. The patch was put onto the 
mucosa and preload (50 g) was added to establish bonding 
between the two, as per the reported method. The weight of 
water required to detach the patch from the buccal mucosa 
was noted. This was taken as a measure of mucoadhesive 
strength. The experiment was repeated with fresh mucosa in 
an identical manner for all the patches and the mean value 
of three readings was reported. Mucoadhesive strength F 
(kg m-1s2) is given by the following equation: 
F= (Ww x g)/ A,
where F is the mucoadhesion force (kg m-1 s 2), Ww is the 
TABLE I - Formula for patches containing acyclovir
Formulation PVP K30 (mg) PEG 400 (ml) Polymer concentration (mg) Drug (mg)
SCMC (polymer)
PS0 0 0.16 400 10
PS1 4 0.16 400 10
PS2 8 0.16 400 10
PS3 12 0.16 400 10
HPMCK4M (polymer)
PH0 0 0.12 300 10
PH1 3 0.12 300 10
PH2 6 0.12 300 10
PH3 9 0.12 300 10
HPMCK15M (polymer)
PE0 0 0.08 200 10
PE1 2 0.08 200 10
PE2 4 0.08 200 10
PE3 6 0.08 200 10
٭SCMC indicates sodium carboxymethyl cellulose; HPMC, hydroxypropyl methylcellulose; PVP, polyvinylpyrrolidone; PEG, 
polyethylene glycol.
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weight of added water, g is acceleration due to gravity 
(cm /s2), and A is the surface area of the patch (cm2) 
(Table III). 
Drug content uniformity of the patches
The drug content of patches was measured without 
the backing membrane. Hydrochloric acid (0.008 mL) 
was taken in a beaker and volume was brought to 10 mL 
with distilled water. The patch was dispersed in 5 mL of 
the solution above and volume was brought to 10 mL with 
pH 6.8 simulated saliva fluid. An analysis was conducted 
for 1 mL of this solution, in order to assess drug content by 
UV spectroscopy (UV1700, Shimadzu, Japan) at 250 nm 
(Bharti, 2007) (Table II).
In vitro residence time
In vitro residence time was determined using a lo-
cally modified USP disintegration apparatus (VTD-AV, 
Veego, India) (Bharti, 2007; Nafee, 2003). The disin-
tegration medium used was 800 ml of simulated saliva 
fluid, pH 6.8, maintained at 37 ºC. A segment of rabbit 
buccal mucosa, with 3 cm in length and 1 cm in width, 
was glued to the surface of a glass plate of similar di-
mensions, and vertically attached to the apparatus. The 
mucoadhesive patch was hydrated from one side with 
2 mL of simulated saliva fluid, which consisted of a phos-
phated buffer saline with a pH of 6.8 and the hydrated 
surface was then brought in contact with the buccal mu-
cosa. The whole assembly was allowed to move up and 
down so that the patch was completely immersed into 
the solution at its lowest position and washed out at its 
highest position. The time required for complete erosion 
or detachment of the patch from the mucosal surface was 
recorded (Table IV).
In vitro membrane permeation studies
Studies were carried out using porcine buccal mu-
cosa obtained from a local slaughterhouse as a model 
membrane. The model membrane was found to be similar, 
in permeability, to the semi-permeable membrane. The 
in vitro permeation studies of acyclovir with the model 
membrane were performed using a modified Keshary 
Chien cell at 37 ± 0.2 ºC (Karlsmark et al., 2008). The 
temperature was maintained at 37 ± 0.2 ºC by a water 
jacket surrounding the receiver chamber. The fresh buc-
cal mucosa was kept in simulated saliva fluid until it was 
used for experimentation, to prevent dehydration of the 
membrane.
Freshly obtained buccal mucosa was mounted be-
tween the donor and receptor compartments. The patch 
was kept over the membrane and the two compartments 
were clamped together. The donor compartment was filled 
with 1 ml of simulated saliva fluid, pH 6.8, and the receptor 
compartment was filled with isotonic phosphate buffer, 
pH 7.4. Hydrodynamics in the receptor compartment was 
maintained by stirring with a magnetic bead at 100 rpm. 
Then, 1 ml of the sample was withdrawn at predetermined 
time intervals (at 1 hour intervals for up to 7 hours) and 
analyzed for drug content by UV Spectroscopy at 250 nm. 
This was replaced, each time, by 1 ml of simulated saliva 
fluid, pH 6.8, at 37 °C.
Phase solubility studies
In order to prepare patches containing the acyclovir 
inclusion complex, phase solubility studies were conduct-
ed to characterize the drug-to-polymer ratio in the inclu-
sion complex (Pavankumar, Ramakrishna, 2005; Mario, 
Becirerics, 2004). The molar ratio of drug-to-polymer was 
optimized based on the solubility studies of acyclovir with 
different concentration of HPBCD. Solubility studies were 
carried out according to the method described by Higuchi 
and Connors (1965). An HPBCD solution was added, 
in different concentrations (2-10 x 10-3 M), to the super-
saturated solution of acyclovir, and then shaken at room 
temperature (for 36 hours). After reaching equilibrium, the 
solution was filtered and the concentration of acyclovir in 
filtrate was determined spectrophotometrically at 250 nm, 
in reference to a suitably constructed standard curve. Also, 
slope and stability constant were calculated from the graph 
including concentration of acyclovir (10-3 M/mL) versus 
concentration of HPBCD (10-3 M/mL). The stability con-
stant K is given by 
K= {(slope/(1-slope)S},
where S is the solubility of the drug in the absence of 
HPBCD.
Preparation of inclusion complexes
The inclusion complex was prepared using the com-
mon solvent method. The polymer HPBCD and acyclovir 
were taken, in a molar ratio of 1:1. The drug and polymer 
were dissolved in a sufficient volume of distilled water by 
stirring. The mixture was heated gently (45 °C) to obtain 
an inclusion complex of acyclovir. The inclusion complex 
was stored in an airtight container until further use (Vamshi 
et al., 2007).
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TABLE II - Formulae for patches containing the inclusion complex of acyclovir
Formulation PVP K30 (mg) PEG 400 (mL) Polymer concentration (mg) Drug (mg)
SCMC (polymer)
PS11 4 0.16 400 10
HPMC K4M (polymer)
PH22 6 0.12 300 10
HPMC K15 (polymer)
PE11 2 0.08 200 10
Characterization of inclusion complexes
Optical microscopy, Mass spectroscopy and FTIR 
spectroscopy were used for the characterization of inclu-
sion complexes
Scanning electron microscopy was used to charac-
terize the drug, polymer HPBCD and inclusion complexes, 
respectively (Philips 505 SEM, Holland.).
Mass spectroscopy was used to characterize the 
mass of the inclusion complex, in order to ascertain the 
proper preparation of inclusion complexes. Samples were 
each mounted on a clean metal tip of the FAB probe and 
then introduced into the spectrometer and characterized in 
a positive mode (FABMS, Jeol SX-102, Japan) (Baboota, 
Dhaliwal, 2005). 
FTIR spectroscopy was used to characterize the drug, 
polymer and inclusion complex in terms of the presence of 
various functional groups (Patel, Poddar, 2009; Alix, Gha-
nia 2003; Mario, Becirerics, 2004). IR spectrum was taken 
for the pure drug, for the pure polymer, and for the drug/
polymer physical mixture, at a wavelength ranging from 
4000 cm-1 to 400 cm-1 (8400S FTIR, Shimadzu, Japan). The 
sample (solid substance) was ground with KBr in the ratio of 
1:100 and was made into a disc after drying in a microwave 
at 160 ºC and then pressed under high temperature and a 
pressure of 6 metric tons. All the spectra were compared 
for shifting of major functional peaks and also for the loss 
of functional peaks, if any, in order to study the interaction 
between drug and polymer (Upendra, Siddhartha, 2010).
Preparation of patches with inclusion complexes
The inclusion complex was incorporated into poly-
mer solutions and the patches were prepared using the 
procedure described above and the formulae shown in 
Table II.
Evaluation of patches with inclusion complexes
Weight uniformity, thickness, swelling index, sur-
face pH, folding endurance, mucoadhesion force, drug 
content and residence time were measured by the methods 
described above. The values are shown in Table V. In vitro 
release studies were performed, as shown in Figure 4.
Scanning electron microscopy was performed for 
the optimized patch in both batches – the first containing 
the drug only and the second containing the inclusion 
complex – to evaluate the uniform distribution of the drug, 
as shown in Figure 5.
RESULTS AND DISCUSSION
Patches were prepared using acyclovir and an acy-
clovir inclusion complex, respectively, since the patches 
of the drug alone exhibited lower balance. The optimized 
formulations in the first batch were PS1, PE1 and PH2 
and in the second batch they were PS11, PE11 and PH22. 
The thickness and weight, surface pH, drug content, and 
folding endurance of the different formulations are shown 
in Tables III and V, for formulations without and with the 
inclusion complex, respectively. 
Thickness was found to vary from 0.12 to 0.26 mm. 
The weight of patches was found to vary from 0.0047 
to 0.0086 g. Folding endurance for patches SCMC, 
HPMC K4M and HPMC K15M was found to be in the 
order of SCMC > 100, HPMCK4M > 80, and HPMC 
K15M > 70, respectively. Surface pH was found to be in 
the range of 5.8 to 6.2 for all the formulations of the two 
batches. Surface pH for all formulations was well within 
range of salivary pH and would not cause irritation in the 
mouth. The swelling indices (Tables IV and V) for the first 
batch were found to be in the order of PS1 > PE1 > PH2, 
whereas, for the second batch, they were in the order of 
PS11 > PE11 > PH22. 
The swelling index for the optimized formulations, 
i.e., PS11, PH22, and PE11, was found to be comparable 
to that of the first batch, i.e., PS1, PH2, and PE1. Mean 
drug content was found to vary between 0.49 and 0.56 mg 
for the different formulations.
For the first batch, mean mucoadhesive strength for 
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TABLE III - Characteristics of buccal mucoadhesive patches containing acyclovir 
Formulation Thickness (mm) Weight (gm) Surface pH Drug content (mg) Folding endurance
PS0 0.17±0.01 0.0047±0.0021 5.8 0.56 123
PS1 0.25±0.04 0.0073±0.0016 5.7 0.52 132
PS2 0.19±0.03 0.0065±0.002 5.6 0.49 127
PS3 0.23±0.05 0.0078±0.0016 5.62 0.50 105
PH0 0.12±0.04 0.0086±0.0009 5.65 0.52 93
PH1 0.17±0.03 0.0071±0.0019 5.25 0.56 92
PH2 0.22±0.05 0.0059±0.0009 6.2 0.52 87
PH3 0.25±0.01 0.0047±0.0046 6.23 0.54 82
PE0 0.27±0.03 0.0050±0.0010 6.03 0.55 73
PE1 0.22±0.04 0.0059±0.0009 5.9 0.49 75
PE2 0.20±0.02 0.0040±0.0010 5.83 0.52 71
PE3 0.26±0.05 0.0054±0.0013 5.76 0.51 70
TABLE IV - Characteristics of buccal mucoadhesive patches containing acyclovir 
Formulation
Swelling index (%) Mucoadhesion force 
(N/m2)
Residence time 
(hours)2 hours 5 hours 7 hours
PS1 40 67 72 5.8± 0.23 5.6±1.35
PE1 23 36 66 6.3±0.27 6.5±1.23
PH2 16 30 60 5.3±0.35 5.2±1.5
TABLE V - Characteristics of buccal mucoadhesive patches containing inclusion complexes
Parameters PS11 PE11 PH22
Thickness (mm) 0.17±0.04 0.15±0.03 0.20±0.05
Weight (gm) 0.0054±0.0013 0.0048±0.0016 0.0086±0.0009
Surface pH 5.8 ±0.3 6.02 ±0.4 5.9 ±0.3
Folding endurance 150 73 82
Drug content (mg) 0.56 0.53 0.54
Swelling index (%)
After 2 hours 39 16 20
After 5 hours 66 28 35
After 7 hours 70 58 62
Mucoadhesion force (N/m2) 5.8±0.201 6.1±0.136 5.5±0.323
Residence time (hours) 5.6±0.208 6.5±0.12 5± 0.35
optimized formulations PS1, PE1, and PH2 was found to 
be 5.8, 6.2, and 5.6 N/m2, respectively, and mean mucoad-
hesive strength was found to be in the order of PE1 > PS1 > 
PH2. For the second batch, mean mucoadhesive strength 
of optimized formulations PS11, PE11, PH22 was found 
to be 5.8, 6.1, and 5.5 N/m2, respectively, and was in the 
order of PE11 > PS11 > PH22. For the first batch, mean 
residence time for formulations PS1, PH2, and PE1 was 
found to be 5.6, 5, and 4.5 hours. For the second batch, 
mean residence time for the optimized formulations was 
found to be 5.6, 6.5 and 5 hours, respectively.
Drug release percentage was greater in formulation 
PS1, from the first batch, and in formulation PS11, from the 
second batch. The release of acyclovir from HPMC patches 
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TABLE VI - Release profile from the optimized formulations with and without the inclusion complex
Cumulative percent drug release from optimized formulations
Time (hours) PS1# PS11* PH2# PH22* PE1# PE11*
1 14.32 3.16 6.23 3.92 7.1 3.57
2 35.06 9.41 7.45 10.29 10.05 12.75
3 39.06 17.02 15.15 17.31 15.23 20.31
4 42.35 28.64 20.69 25.68 25.37 32.78
5 48.15 45.56 23.32 34.90 35.11 42.56
6 59.23 65.35 28.15 44.65 40.13 51.31
7 64.35 88.15 33.73 55.53 43.57 62.34
* with inclusion complex ; # without inclusion complex
was slower when compared to that of SCMC patches. In 
the first batch, the cumulative release percentage from 
the optimized formulations PH2 and PE1, respectively, 
was 33.73% and 43.57% in 7 hours, whereas the cumula-
tive release percentage from SCMC (PS1) was 64.35%. 
This was attributed to low aqueous solubility of polymers 
HPMC K4M and HPMC K15M. Out of the two sustaining 
polymers, HPMC K15M showed higher drug release due 
to higher swelling, when compared to HPMC K4M. The 
release profile from optimized formulation PS11 contain-
ing the inclusion complex was 88.15%, which was much 
higher than the value for formulation PS1 (64.35%). With 
regard to the second batch, formulations PE11 and PH22 
with inclusion complexes released 62.34% and 55.53 % of 
the drug, respectively, whereas formulations PE1 and PH2 
with the drug alone released 43.57% and 33.73% of the 
drug, respectively, in a time interval of 7 hours. (Table VI)
Swelling controlled release system is given by 
equation
MT/M∞ = Ktn,
where Mt/M∞ = fraction of drug released, T = release 
time, K = constant incorporating structural and geometri-
cal characteristics of controlled system, and n = release 
exponent.
When n < 0.5, release is said to be Fickian, con-
trolled by the diffusion of the drug, and when n = 0.5-1, 
release is said to be non-Fickian. Here, the value of n for 
all the formulations was found to be between 0.5 and 1, 
suggesting that the drug follows non-Fickian release and 
is released by both erosion and diffusion mechanisms.
SCMC is a hydrophilic polymer, which swelled 
during dissolution, forming a gel layer. The loosely bound 
polymer molecules were easily eroded, allowing release 
of acyclovir at a faster rate, when compared to other cellu-
losic derivatives. The inclusion complex further enhanced 
drug release by incorporating the drug in its cavity and 
preventing direct contact of water-insoluble drug with the 
medium. From the release studies, it was found that the 
drug followed zero-order release kinetics. Phase solubil-
ity studies were performed to characterize the ratio of 
polymer-to-drug. Since the slope of the diagram was less 
than 1 (0.0001), the complex stoichiometry was observed 
to be 1:1. Value of the stability constant was found to be 
11.98. A linear increase in the solubility of acyclovir was 
observed with increased concentration of HPBCD.
Therefore, the molar ratio of drug-to-HPBCD was 
taken to be 1:1. SEM analysis showed that the drug was 
crystalline in nature and that crystals were transparent. The 
polymer was found to be amorphous in nature. The inclu-
sion complex was found to be crystalline in nature, having 
translucent crystals showing an association between the 
drug acyclovir and the polymer HPBCD (Figure 1). 
Mass spectroscopy was used as a technique to con-
firm the formation of inclusion complex of acyclovir in a 
1:1 molar ratio with HPBCD. The mass spectrum of the 
pure drug, polymer HPBCD, and the inclusion complex 
was taken and analyzed for molecular ion peak. It was 
found that polymer, drug and inclusion complex showed 
peaks at their respective molecular mass (Figure 2).
FTIR spectrum of acyclovir polymer and inclusion 
complex showed the presence of peaks: N-H stretching 
vibrations at 3301 cm-1, 3442 cm-1, N-H bending vibra-
tions at 1585.38 cm-1, 1610.45 cm-1, C-N stretching of 
primary amines at 1309.56 cm-1, and aromatic nucleus in 
the drug at 781.12 cm-1. Polymer HPBCD showed peaks 
at C-H stretching (2927.74 cm-1, 1157.21 cm-1), aromatic 
nucleus (657.66 cm-1, 705.90 cm-1, 756.04 cm-1), O-H 
stretching (3479.34 cm-1). The inclusion complex IR 
spectrum showed disappearance of O-H stretching and 
N-H stretching peaks, indicating interaction between 
the hydroxyl group of the polymer HPBCD and the drug 
acyclovir (Figure 3).
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FIGURE 1 - SEM Photo micrographs of (a) acyclovir, and (b) acyclovir inclusion complex.
FIGURE 2 - Mass spectrum of (a) acyclovir, and (b) inclusion complex.
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FIGURE 3 - Fourier transform infrared spectrum of inclusion complex.
FIGURE 4 - Release profile of acyclovir from patches with 
inclusion complex.
FIGURE 5 - SEM of patches containing (a) acyclovir, and (b) acyclovir inclusion complex.
A substantial increase in the cumulative release per-
centage of acyclovir was observed in the case of patches 
containing inclusion complex (Table VI and Figure 4), 
which was approximately 20% in each case, i.e., PS I and 
PS II, PH2 and PH22, and PEI and PEII, respectively. This 
could be attributed to the increased solubility of drug with 
the use of the HPBCD inclusion complex.
The patches were analyzed for uniform distribu-
tion of the drug in the optimized formulations PS1 and 
PS11 by scanning electron microscopy. It was found 
that the drug was more uniformly suspended in the 
patch containing the drug alone (Figure 5), in com-
parison with the patch containing the drug polymer 
inclusion complex. However, the benefit of increased 
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bioavailability outweighed this anomaly in physical 
parameters.
CONCLUSION
The incorporation of acyclovir inclusion complex 
into buccal patches was able to substantially enhance the 
percentage of drug released from the patches, thereby 
increasing bioavailability. Transmucosal buccal delivery 
of acyclovir could be developed as a potential method for 
the treatment of herpes simplex infections.
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